November 08, 2013
Sutter Health pays $46 million in case alleging false, misleading surgery bills
The effectiveness of the whistleblower reward program under the California Department of Insurance was demonstrated earlier this week when Sutter Health agreed to a $46 million settlement in a case alleging...
Posted In Whistleblower Law Insights
November 01, 2013
Medical device company unintentionally highlights the problem with doctor ownership
The coincidental timing of a new government report and a recent lawsuit show that some medical device companies just don’t get why it’s not a good idea for doctors to have financial arrangements with...
Posted In Whistleblower Law Insights
October 01, 2013
SEC makes good on promise for large whistleblower reward soon
The Securities and Exchange Commission (SEC) announced today that it has awarded $14 million to a whistleblower for information and assistance. This is the largest SEC whistleblower reward so far under...
September 27, 2013
JP Morgan settlement criticized
The Securities and Exchange Commission settlement of a case against JPMorgan without charging any top executives, was heavily criticized by Jesse Eisinger, a finance reporter for ProPublica in a New York...
September 23, 2013
FDA bans Ranbaxy imports – again – for pharma manufacturing concerns
For the third time in five years, the U.S. Food and Drug Administration has blocked imports of medicine from a Ranbaxy Laboratories Ltd. plant in India for manufacturing violations. The latest ban involves...
Posted In Whistleblower Law Insights
September 16, 2013
Vanderbilt University hospital accused of failing to supervise doctors and nurses in training during surgeries
A “qui tam” lawsuit against the Vanderbilt University Medical Center that was unsealed last week contained a particularly disturbing allegation: It cited an incident where an unsupervised student nurse...
Posted In Whistleblower Law Insights
September 13, 2013
Bayer AG is the latest pharma company to acknowledge it is being investigated by Chinese authorities for its marketing and sales practices in China
Given the growing number of pharma companies in China under investigation for bribery and corruption, it’s becoming more a question of who isn’t being investigated, rather than who is. Pharma companies...
Posted In Whistleblower Law Insights
September 11, 2013
Glaxo getting squeezed by three countries for pharma marketing practices in China
After getting slapped by the U.S. in 2012 for its marketing practices, GlaxoSmithKline now is getting pummeled by China, the UK, and the U.S. which are investigating Glaxo for its pharma marketing practices...
Posted In Whistleblower Law Insights
April 24, 2013
Review of Barclays fails to recognize role whistleblowers can play in compliance
A recent independent report on British bank Barclays corporate culture, known as the Salz Review, addresses the impact some employees’ conduct has had on the bank’s reputation. It does not, however,...
Posted In Whistleblower Law Insights
March 27, 2013
Texas reaps rewards of whistleblower cases
A new report issued by the Taxpayers Against Fraud Education Fund highlights the substantial benefits states realize from adopting false claims laws. Fighting Medicaid Fraud in Texas, authored by economists...
Posted In Whistleblower Law Insights